A Phase 1b Study of SMT C1100 in Subjects With Duchenne Muscular Dystrophy (DMD)
NCT02056808
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
12
Enrollment
INDUSTRY
Sponsor class
Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG:
SMT C1100
Sponsor
Summit Therapeutics